4
17
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T35463 |
(±)14(15)-EET
(±)14,15-EET,(±)14,15-EpETrE,(±)14(15)-EET |
||
(±)14(15)-EET is a metabolite of arachidonic acid that is formed via epoxidation of arachidonic acid by cytochrome P450.[1],[2] It prevents increases in leukotriene B4, ICAM-1, and chemokine (C-C motif) ligand 1 (CCL2) induced by oxidized LDL in primary rat pulmonary artery endothelial cells (RPAECs) when used at a concentration of 1 μM.[3] (±)14(15)-EET induces dilation of preconstricted isolated canine coronary arterioles (EC50 = 0.2 pM).[4] It reduces myocardial infarct size as a percentage o... | |||
T36070 |
(±)5(6)-EET
|
||
5(6)-EET is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes. In solution, 5(6)-EET degrades into 5,6-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS. In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5(6)-EET has been implicated in the mobilization of calcium and hormone secretion. 5(6)-EET is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhib... | |||
T36152 |
14S(15R)-EET
|
||
14S(15R)-EET is an oxylipin and a cytochrome P450 metabolite of arachidonic acid .114S(15R)-EET binds to isolated guinea pig monocytes with a Kivalue of 612.5 nM in a competitive binding assay using [3H]14(15)-EET.2It induces dilation of precontracted isolated canine epicardial arterioles (EC50= 4 pM) and denuded porcine subepicardial arterioles (EC50= 3 pM).3Unlike 14R(15S)-EET, 14S(15R)-EET does not inhibit COX in enzyme assays or isolated platelets.4 1.Daikh, B.E., Lasker, J.M., Raucy, J.L., ... | |||
T35494 |
(±)11(12)-EET
|
||
(±)11(12)-EET is a fully racemic version of the R/S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.[1][2][3[]A higher proportion of 11(R),12(S)-EET is produced by the CYP450 isoforms CYP2C23 and CYP2C24 while CYP2B2 produces a higher proportion of 11(S),12(R)-EET.[3]11(12)-EET has been shown, along with 8(9)-EET to play a role in the recovery of depleted calcium pools in cultured smooth muscle cells[4] It also inhibits basolateral 18-pS potassium channels in t... |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-02234 |
CXCL9 Protein, Human, Recombinant
MIG,CMK,Humig,chemokine ... |
Human | E. coli |
CXCL9 Protein, Human, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 11.9 kDa and the accession number is Q07325. | |||
TMPY-03274 |
CXCL11 Protein, Human, Recombinant
SCYB9B,I-TAC, |
Human | E. coli |
I-TAC, also known as CXCL11, is a small cytokine belonging to the CXC chemokine family. It is highly expressed in peripheral blood leukocytes, pancreas and liver, with moderate levels in thymus, spleen and lung and low expression levels were in small intestine, placenta and prostate. The I-TAC chemokine elicits its effects on its target cells by interacting with the cell surface chemokine receptor CXCR3, with a higher affinity than do the other ligands for this receptor, CXCL9 and CXCL10. I-TAC ... | |||
TMPY-04255 |
CXCL9 Protein, Rhesus, Recombinant
chemokine (C-X-C... |
Rhesus | E. coli |
CXCL9 Protein, Rhesus, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 11.9 kDa and the accession number is Q8MIZ2. | |||
TMPY-02203 |
CXCL9 Protein, Mouse, Recombinant
BB139920,Scyb9,... |
Mouse | E. coli |
CXCL9 Protein, Mouse, Recombinant is expressed in E. coli expression system. The predicted molecular weight is 12.3 kDa and the accession number is P18340. | |||
TMPJ-01084 |
CXCL9 Protein, Human, Recombinant (His)
Monokine Induced by Interferon-γ,Gamma-Int... |
Human | HEK293 Cells |
Chemokine (C-X-C Motif) Ligand 9 (CXCL9) belongs to the intercrine alpha (chemokine CXC) family. It is secreted by interferon stimulated monocytes, macrophages and endothelial cells, which elicits chemotactic functions by interacting with the chemokine receptor CXCR3. CXCL9 acts as a Th1 (type 1 helper T) cell chemoattractant and plays a role in the growth, activation and movement of cells associated with immune and inflammatory responses, and in tumour growth inhibition. It is closely related t... | |||
TMPJ-01000 |
CCL9 Protein, Mouse, Recombinant
Macrophage inflammatory protein 1-gamma,Ma... |
Mouse | E. coli |
C-C motif chemokine 9(CCL9) is an 11 kDa, secreted, monomeric polypeptide that belongs to the beta (or CC) intercrine family of chemokines. It is expressed mainly in the liver, lung, and the thymus, although some expression has been detected in a wide variety of tissues except brain. Monokine has inflammatory, pyrogenic and chemokinetic properties. It circulates at high concentrations in the blood of healthy animals. Binding to a high-affinity receptor,it activates calcium release in neutrophils... | |||
TMPJ-00884 |
CXCL9 Protein, Mouse, Recombinant (His)
Protein m119,C-X-C |
Mouse | HEK293 Cells |
Chemokine (C-X-C motif) ligand 9 (CXCL9, MIG), is a small cytokine belonging to the CXC chemokine family. CXCL9 functions as one of the three ligands of chemokine receptor CXCR3 which is a G protein-coupled receptor found predominantly on T cells. It together with CXCL10 and CXCL11, may activate CXCR3 by binding to it. CXCL9 serves as a cytokine that affects the growth, movement, or activation state of cells that participate in immune and inflammatory response. It has been observed that tumour e... | |||
TMPJ-01060 |
CXCL6 Protein, Human, Recombinant (His)
SCYB6,Chemokine Alpha 3,... |
Human | HEK293 Cells |
Chemokine (C-X-C-Motif) Ligand 6 (CXCL6) is a small cytokine belonging to the CXC chemokine family. It is a potent neutrophil chemotactic and activating factor and it exhibits extensive similarity to other CXC chemokines such as IL-8 and ENA-78. CXCL6 can promote the release of MMP-9 from granulocytes indicating its potential role as an inflammatory mediator. It functionally uses both of the IL-8/CXCL8 receptors to chemoattract neutrophils but that is structurally most related to epithelial cell... | |||
TMPJ-00865 |
VEGF121 Protein, Human, Recombinant (His)
VEGFA,VEGF-A,Vascular permeability fa<... |
Human | HEK293 Cells |
Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessel... | |||
TMPY-03698 |
VEGF121b Protein, Human, Recombinant
MVCD1,VEGF,VPF,vascular ... |
Human | HEK293 Cells |
VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9. | |||
TMPH-00005 |
YAP1 Protein, Human, Recombinant (Isoform 9, His)
YAP1-2delta |
Human | P. pastoris (Yeast) |
YAP1 Protein, Human, Recombinant (Isoform 9, His) is expressed in yeast with C-6xHis tag. The predicted molecular weight is 56.4 kDa; 80 kDa, reducing conditions and the accession number is P46937-9. | |||
TMPK-00825 |
VEGF121 Protein, Human, Recombinant (His & Avi)
VPF,VEGF,VEGFA,VEGFMGC70609,血管内皮生... |
Human | HEK293 Cells |
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 17 kDa and the accession number is P15692-9. | |||
TMPK-00826 |
VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated
VAS,VEGFMGC70609,RP1-261G23.1,血管内... |
Human | HEK293 Cells |
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 17 kDa and the accession number is P15692-9. | |||
TMPY-05268 |
Neurofascin Protein, Human, Recombinant (hFc), Biotinylated
NRCAML,neurofascin,NF |
Human | HEK293 Cells |
Neurofascin Protein, Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 130 kDa and the accession number is O94856-9. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,C... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRA... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |